Validation Data Gallery
|Positive WB detected in||Jurkat cells, mouse testis tissue, K-562 cells, HeLa cells, mouse thymus tissue|
|Positive IP detected in||mouse testis tissue|
|Positive IF detected in||HeLa cells|
|Western Blot (WB)||WB : 1:200-1:1000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:200-1:1000 for WB|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
10215-1-AP targets FANCG in WB, IP, IF, ELISA applications and shows reactivity with human, mouse, rat samples.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||FANCG fusion protein Ag0249|
|Full Name||Fanconi anemia, complementation group G|
|Calculated molecular weight||69 kDa|
|Observed molecular weight||65-68 kDa|
|GenBank accession number||BC000032|
|Gene ID (NCBI)||2189|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
FANCG, also named as XRCC9, is a vDNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. It's a candidate tumor suppressor gene. FANCA and FANCG are critical for the localization of the FANC core complex. FANCA and FANCG form a stable complex with a molecular weight of ∼500 kDa that is predicted to be a heterotetramer (PMID: 32002546).
Deficiency in mammalian STN1 promotes colon cancer development via inhibiting DNA repair
Significant value of XRCC2 and XRCC9 expression in the prognosis of human ovarian carcinoma.
Clin Transl Oncol
Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.